160 related articles for article (PubMed ID: 35748327)
1. Comparative effectiveness and safety of edoxaban, rivaroxaban, and apixaban in patients with venous thromboembolism: A cohort study.
Fukasawa T; Seki T; Nakashima M; Kawakami K
J Thromb Haemost; 2022 Sep; 20(9):2083-2097. PubMed ID: 35748327
[TBL] [Abstract][Full Text] [Related]
2. Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data.
Dawwas GK; Leonard CE; Lewis JD; Cuker A
Ann Intern Med; 2022 Jan; 175(1):20-28. PubMed ID: 34871048
[TBL] [Abstract][Full Text] [Related]
3. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials.
Chen J; Lv M; Wu S; Jiang S; Xu W; Qian J; Chen M; Fang Z; Zeng Z; Zhang J
Eur J Vasc Endovasc Surg; 2022 Mar; 63(3):465-474. PubMed ID: 34973879
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
5. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
6. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
7. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
Dawwas GK; Brown J; Dietrich E; Park H
Lancet Haematol; 2019 Jan; 6(1):e20-e28. PubMed ID: 30558988
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.
Sindet-Pedersen C; Staerk L; Pallisgaard JL; Gerds TA; Berger JS; Torp-Pedersen C; Gislason GH; Olesen JB
Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):220-227. PubMed ID: 29945162
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Skjøth F; Larsen TB; Rasmussen LH; Lip GY
Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
[TBL] [Abstract][Full Text] [Related]
14. Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis.
Feng W; Wang X; Huang D; Lu A
Pharmacol Res; 2021 Apr; 166():105438. PubMed ID: 33540046
[TBL] [Abstract][Full Text] [Related]
15. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study.
Marston XL; Wang R; Yeh YC; Zimmermann L; Ye X; Gao X; Brüggenjürgen B; Unverdorben M
Int J Cardiol; 2022 Jan; 346():93-99. PubMed ID: 34780886
[TBL] [Abstract][Full Text] [Related]
17. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies.
Fredman D; McNeil R; Eldar O; Leader A; Gafter-Gvili A; Avni T
J Thromb Thrombolysis; 2024 Mar; 57(3):453-465. PubMed ID: 38127261
[TBL] [Abstract][Full Text] [Related]
19. Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.
Wu S; Lv M; Chen J; Jiang S; Chen M; Fang Z; Zeng Z; Qian J; Xu W; Guan C; Zhang J
Support Care Cancer; 2022 Dec; 30(12):10407-10420. PubMed ID: 36318341
[TBL] [Abstract][Full Text] [Related]
20. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
Howe Z; Naville-Cook C; Cole D
J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
